Georgiana Constantinescu1, Steffen Leike2, Matthias Gruber1, Katharina Langton3, Carola Kunath3, Mirko Peitzsch3, Jaap Deinum1,4, Graeme Eisenhofer3, Jacques Lenders1,4. 1. Department of Endocrinology, Internal Medicine III, Dresden, Germany. 2. Department of Urology, Dresden, Germany. 3. Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 4. the Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
Abstract
OBJECTIVE: Both clinical suspicion and diagnosis of pheochromocytoma (PCC) can be challenging in patients where the presentation can be confused with the pharmacophysiological effects of illicit drugs known to activate the sympathetic nervous system. We report on such a patient and outline considerations that can impact diagnostic decision making. METHODS: Clinical examination, measurement of plasma metanephrines, followed by magnetic resonance imaging, iodine 123-metaiodobenzylguanidine single-photon emission computed tomography, and histopathology of the resected tumor. RESULTS: A 35-year-old male patient was referred to our center because of a right-sided adrenal mass, incidentally found during an abdominal ultrasound performed due to nausea, vomiting, and lumbar pain. Although he had no history of hypertension, he had complained for over 6 years of severe episodic headache, panic attacks, and profuse sweating. He also had a longer history of methamphetamine abuse. Plasma concentrations of metanephrine (10.7 pmol/L) and normetanephrine (3.83 pmol/L) were 25-fold and 5.6-fold above respective upper limits of reference intervals (0.42 and 0.69 pmol/L). This indicated a PCC, which was confirmed after adrenalectomy. Failure to recognize the patient's signs and symptoms as attributable to a PCC was unsurprising given that methamphetamine abuse can result in many of the same signs and symptoms as a catecholamine-producing tumor. CONCLUSION: The abuse of drugs such as methamphetamine can obscure an underlying PCC due to the similarity of several symptoms associated with both conditions. Recognition of a PCC in patients using illicit drugs such as methamphetamine remains challenging.
OBJECTIVE: Both clinical suspicion and diagnosis of pheochromocytoma (PCC) can be challenging in patients where the presentation can be confused with the pharmacophysiological effects of illicit drugs known to activate the sympathetic nervous system. We report on such a patient and outline considerations that can impact diagnostic decision making. METHODS: Clinical examination, measurement of plasma metanephrines, followed by magnetic resonance imaging, iodine 123-metaiodobenzylguanidine single-photon emission computed tomography, and histopathology of the resected tumor. RESULTS: A 35-year-old male patient was referred to our center because of a right-sided adrenal mass, incidentally found during an abdominal ultrasound performed due to nausea, vomiting, and lumbar pain. Although he had no history of hypertension, he had complained for over 6 years of severe episodic headache, panic attacks, and profuse sweating. He also had a longer history of methamphetamine abuse. Plasma concentrations of metanephrine (10.7 pmol/L) and normetanephrine (3.83 pmol/L) were 25-fold and 5.6-fold above respective upper limits of reference intervals (0.42 and 0.69 pmol/L). This indicated a PCC, which was confirmed after adrenalectomy. Failure to recognize the patient's signs and symptoms as attributable to a PCC was unsurprising given that methamphetamine abuse can result in many of the same signs and symptoms as a catecholamine-producing tumor. CONCLUSION: The abuse of drugs such as methamphetamine can obscure an underlying PCC due to the similarity of several symptoms associated with both conditions. Recognition of a PCC in patients using illicit drugs such as methamphetamine remains challenging.
Authors: Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Massimo Mannelli; Jacques W M Lenders; Karel Pacak; Gabriele Parenti; Graeme Eisenhofer Journal: Best Pract Res Clin Endocrinol Metab Date: 2012-05-22 Impact factor: 4.690
Authors: Y Lu; P Li; W Gan; X Zhao; S Shen; W Feng; Q Xu; Y Bi; H Guo; D Zhu Journal: Exp Clin Endocrinol Diabetes Date: 2016-05-24 Impact factor: 2.949
Authors: Aikaterini Geroula; Timo Deutschbein; Katharina Langton; Jimmy Masjkur; Christina Pamporaki; Mirko Peitzsch; Stephanie Fliedner; Henri J L M Timmers; Stefan R Bornstein; Felix Beuschlein; Anthony Stell; Andrzej Januszewicz; Aleksander Prejbisz; Martin Fassnacht; Jacques W M Lenders; Graeme Eisenhofer Journal: Eur J Endocrinol Date: 2019-10 Impact factor: 6.664
Authors: Natalie Rogowski-Lehmann; Aikaterini Geroula; Aleksander Prejbisz; Henri J L M Timmers; Felix Megerle; Mercedes Robledo; Martin Fassnacht; Stephanie Fliedner; Martin Reincke; Anthony Stell; Andrzej Januszewicz; Jacques Lenders; Graeme Eisenhofer; Felix Beuschlein Journal: Endocr Connect Date: 2018-09-01 Impact factor: 3.335